FibroBiologics Leadership Authors Opinion Editorial Highlighting Fibroblast Cells' Therapeutic Advantages Over Traditional Stem Cell Therapies
FibroBiologics (NASDAQ: FBLG) has published an opinion editorial highlighting the potential advantages of fibroblast cells over traditional stem cell therapies. The article, authored by CEO Pete O'Heeron and CSO Hamid Khoja, Ph.D., presents research supporting fibroblasts' superior characteristics including faster proliferation rates, better sourcing capabilities, and enhanced immune modulation properties.
The company's research focuses on treating chronic diseases such as multiple sclerosis, rheumatoid arthritis, and wound healing applications. With 270+ issued and pending patents, FibroBiologics positions fibroblast-based solutions as potentially superior to mesenchymal stem cells in terms of clinical utility, safety profile, and scalability.
FibroBiologics (NASDAQ: FBLG) ha pubblicato un editoriale di opinione che mette in evidenza i potenziali vantaggi delle cellule fibroblasti rispetto alle terapie tradizionali con cellule staminali. L'articolo, scritto dal CEO Pete O'Heeron e dal CSO Hamid Khoja, Ph.D., presenta ricerche che supportano le caratteristiche superiori dei fibroblasti, tra cui rapidi tassi di proliferazione, migliori capacità di reperimento e proprietà potenziate di modulazione immunitaria.
La ricerca dell'azienda si concentra sul trattamento di malattie croniche quali sclerosi multipla, artrite reumatoide e applicazioni per la guarigione delle ferite. Con oltre 270 brevetti rilasciati e in attesa, FibroBiologics posiziona le soluzioni basate sui fibroblasti come potenzialmente superiori alle cellule staminali mesenchimali in termini di utilità clinica, profilo di sicurezza e scalabilità.
FibroBiologics (NASDAQ: FBLG) ha publicado un editorial de opinión que destaca las posibles ventajas de las células fibroblastos frente a las terapias tradicionales con células madre. El artículo, escrito por el CEO Pete O'Heeron y el CSO Hamid Khoja, Ph.D., presenta investigaciones que respaldan las características superiores de los fibroblastos, entre las que se encuentran tasas de proliferación más rápidas, mejores capacidades de obtención y propiedades mejoradas de modulación inmunitaria.
La investigación de la empresa se centra en tratar enfermedades crónicas como esclerosis múltiple, artritis reumatoide y aplicaciones de curación de heridas. Con más de 270 patentes emitidas y pendientes, FibroBiologics posiciona las soluciones basadas en fibroblastos como potencialmente superiores a las células madre mesenquimales en términos de utilidad clínica, perfil de seguridad y escalabilidad.
FibroBiologics (NASDAQ: FBLG)가 섬유아세포를 전통적 줄기세포 치료법보다 우월하다고 강조하는 의견 신문 기고문을 발표했습니다. CEO Pete O'Heeron과 CSO Hamid Khoja, Ph.D.가 작성한 이 글은 더 빠른 증식 속도, 더 나은 소싱 능력, 향상된 면역 조절 특성 등 섬유아세포의 우수한 특성을 뒷받침하는 연구를 제시합니다.
회사의 연구는 다발성 경화증, 류마티스 관절염, 상처 치유 응용과 같은 만성 질환의 치료에 초점을 맞추고 있습니다. 발행 및 보류 중인 특허 270건 이상으로 FibroBiologics는 섬유아세포 기반 솔루션을 임상적 활용성, 안전성 프로필 및 확장성 면에서 중간엽 줄기세포보다 우수하다고 제시합니다.
FibroBiologics (NASDAQ: FBLG) a publié un éditorial d’opinion soulignant les avantages potentiels des cellules fibroblastiques par rapport aux thérapies traditionnelles à base de cellules souches. L’article, rédigé par le PDG Pete O'Heeron et le CSO Hamid Khoja, Ph.D., présente des recherches soutenant les caractéristiques supérieures des fibroblastes, notamment des taux de prolifération plus rapides, de meilleures capacités de sourcing et des propriétés de modulation immunitaire améliorées.
Les recherches de l’entreprise se concentrent sur le traitement de maladies chroniques telles que la sclérose en plaques, l’arthrite rhumatoïde et les applications de cicatrisation des plaies. Avec plus de 270 brevets délivrés et en attente, FibroBiologics positionne les solutions à base de fibroblastes comme potentiellement supérieures aux cellules souches mésenchymateuses en termes d’utilité clinique, de profil de sécurité et de scalabilité.
FibroBiologics (NASDAQ: FBLG) hat einen Meinungsartikel veröffentlicht, der die potenziellen Vorteile von Fibroblasten gegenüber herkömmlichen Stem-cell-Therapien hervorhebt. Der Artikel, verfasst von CEO Pete O'Heeron und CSO Hamid Khoja, Ph.D., präsentiert Forschungsergebnisse, die die überlegenen Eigenschaften von Fibroblasten unterstützen, darunter schnellere Proliferationsraten, bessere Beschaffungskapazitäten und verbesserte Immunmodulations-Eigenschaften.
Das Forschungsfokus des Unternehmens liegt auf der Behandlung chronischer Erkrankungen wie Multiple Sklerose, rheumatoide Arthritis und Wundheilungsanwendungen. Mit mehr als 270 ausgegebenen und anhängigen Patenten positioniert FibroBiologics fibroblast-basierte Lösungen als potentiell überlegen gegenüber mesenchymalen Stammzellen hinsichtlich klinischer Nützlichkeit, Sicherheitsprofil und Skalierbarkeit.
FibroBiologics (NASDAQ: FBLG) نشرت عمود رأي يبرز الفوائد المحتملة لخلايا الألياف اللفافية (الفايبر بلاست) مقارنة بالعلاجات التقليدية بالخلايا الجذعية. المقال، الذي كتبه الرئيس التنفيذي بيت أوهيرون وCFO عِبْد حميد خوجا، دكتوراه، يعرض أبحاث تدعم الخصائص المتفوقة للفايبر بلاست بما في ذلك معدلات التكاثر الأسرع، وقدرات الاست sourcing الأفضل، وخصائص تنظيم مناعي معززة.
تركز أبحاث الشركة على علاج أمراض مزمنة مثل التصلب المتعدد، التهاب المفاصل الروماتويدي، وتطبيقات شفاء الجروح. مع أكثر من 270 براءة اختراع منتهية وقيد النظر، تضع FibroBiologics الحلول القائمة على الفايبر بلاست كخيار قد يكون أعلى من الخلايا جذعية مائية المتوسطة قيمة من حيث الفائدة السريرية، ملف السلامة، وقابلية التوسع.
FibroBiologics (NASDAQ: FBLG) 已发表一篇观点社论，强调成纤维细胞相较于传统干细胞疗法的潜在优势。该文由首席执行官 Pete O'Heeron 与首席科学官 Hamid Khoja，博士共同撰写，介绍支持成纤维细胞具备< b>更快的增殖速率、 更好的获取能力、以及增强的免疫调节特性等优越特征的研究。
公司研究聚焦于治疗慢性疾病，如 多发性硬化、类风湿性关节炎，以及创伤愈合应用。随着 已发明及待专利超过270项，FibroBiologics 将以成纤维细胞为基础的解决方案定位为在临床实用性、安全性以及可扩展性方面可能优于间充质干细胞的选项。
- None.
- Company faces liquidity and capital resource maintenance challenges
- Clinical study results are unpredictable and may not match R&D expectations
- Success of patent applications prosecution is uncertain
HOUSTON, Sept. 12, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced the publication of an opinion editorial authored by company leadership that presents the scientific case for fibroblast cells' therapeutic advantages compared to stem cell therapies.
The article, titled “Fibroblast Cells vs. Stem Cells: A Superior Option for Chronic Disease Therapy,” was authored by Pete O'Heeron, Founder and Chief Executive Officer of FibroBiologics, and Hamid Khoja, Ph.D., Chief Scientific Officer. The editorial presents a comprehensive review of published research and FibroBiologics’ long-term internal scientific studies supporting the advantages that fibroblast cells offer over stem cells in treating chronic diseases, including faster proliferation rates, superior sourcing capabilities, and enhanced immune modulation properties for conditions such as multiple sclerosis, rheumatoid arthritis, and wound healing applications.
“What we’re seeing is the beginning of a paradigm shift in medicine — one that will positively transform how chronic disease is treated,” said Mr. O’Heeron. “Based on our extensive research using fibroblasts, the evidence is clear: fibroblasts aren’t just comparable to mesenchymal stem cells, they may actually be superior. They offer scalability, effectiveness, and the potential to truly modify disease at scale. This is about building for the long term — a future where therapies don’t just manage illness, they fundamentally change patient outcomes.”
“Our commentary synthesizes the growing evidence base that supports the transition from stem cell therapies to fibroblast-based solutions,” said Dr. Khoja. “Publications and our internal research demonstrate the potential superiority of fibroblasts in clinical utility, safety profile, scalability for clinical use, and potentially improved patient outcomes across multiple therapeutic areas.”
For more information, please visit FibroBiologics' website or email FibroBiologics at: info@fibrobiologics.com.
Cautionary Statement Regarding Forward-Looking Statements
This communication contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include information concerning the potential advantages of fibroblast cells over stem cells and the potential of fibroblast cell therapies and of such treatments to revolutionize the treatment of chronic diseases. These forward-looking statements are based on FibroBiologics' management's current expectations, estimates, projections and beliefs, as well as a number of assumptions concerning future events. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside FibroBiologics' management's control, that could cause actual results to differ materially from the results discussed in the forward-looking statements, including those set forth under the caption "Risk Factors" and elsewhere in FibroBiologics' annual, quarterly and current reports (i.e., Form 10-K, Form 10-Q and Form 8-K) as filed or furnished with the SEC and any subsequent public filings. Copies are available on the SEC's website, www.sec.gov. These risks, uncertainties, assumptions and other important factors include, but are not limited to: (a) risks related to FibroBiologics' liquidity and its ability to maintain capital resources sufficient to conduct its business; (b) expectations regarding the initiation, progress and expected results of FibroBiologics’ R&D efforts and preclinical studies; (c) the unpredictable relationship between R&D and preclinical results and clinical study results; and (d) the ability of FibroBiologics to successfully prosecute its patent applications. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FibroBiologics assumes no obligation and, except as required by law, does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. FibroBiologics gives no assurance that it will achieve its expectations.
About FibroBiologics
Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 270+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, visit www.FibroBiologics.com.
General Inquiries:
info@fibrobiologics.com
Investor Relations:
Nic Johnson
Russo Partners
(212) 845-4242
fibrobiologicsIR@russopr.com
Media Contact:
Liz Phillips
Russo Partners
(347) 956-7697
Elizabeth.phillips@russopartnersllc.com
FAQ
What advantages do FibroBiologics' (FBLG) fibroblast cells have over stem cells?
What chronic diseases is FibroBiologics (FBLG) targeting with its fibroblast technology?
How many patents does FibroBiologics (FBLG) currently have?
What are the main risks facing FibroBiologics' (FBLG) development programs?
Who authored the FibroBiologics (FBLG) opinion editorial on fibroblast cells?
